TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27005498
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (rehydration, correction of acidosis, oral smecta, intestinal probiotics) in control group (60 cases)
Study: 27005498
Drug: Low lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactose milk powder feeding in treatment group
Study: 27005498
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in control group
Study: 20073409
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of daily OxyContin
Study: 20073409
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of daily OxyContin
Study: 20073409
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of daily OxyContin
Study: 16962929
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day for 14 days
Study: 8548465
Drug: Ioxaglate (Hexabrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (Hexabrix 320; 40 to 240 mL, mean 141 mL)
Study: 8548465
Drug: Ioversol (Optiray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioversol (Optiray 320; 20 to 180 mL, mean 87 mL)
Study: 1808526
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections with Depo‐Medrol or Polcortolon plus bupivacaine
Study: 1808526
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections with Polcortolon plus bupivacaine
Study: 31778446
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/day for 16 weeks
Study: 31778446
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral isotretinoin 0.3-0.4 mg/kg for 16 weeks
Study: 30327236
Drug: Sequential or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential or radiotherapy alone
Study: 28807086
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids followed by intranasal steroids (Group A)
Study: 28807086
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids alone (Group B)
Study: 24229669
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy (including a single injection of basal insulin and basal insulin plus preprandial insulin)
Study: 24229669
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin therapy
Study: 20642328
Drug: Support group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support group participation (12 monthly support group meetings)
Study: 19542400
Drug: Low-dose unenhanced
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unenhanced CT
Study: 19542400
Drug: Standard-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose i.v. contrast-enhanced CT
Study: 16942934
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with the most common genotype combination of SNPs (‐604G/A, ‐501A/C, Leu72Met, Gln90Leu)
Study: 15501741
Drug: Valium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valium (0.1 mg/kg)
Study: 15501741
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (50 mg/kg)
Study: 15501741
Drug: Valium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valium (0.1 mg/kg) and Magnesium sulfate (50 mg/kg)
Study: 9366103
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/hydrochlorothiazide 12.5 mg
Study: 9366103
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg/hydrochlorothiazide 25 mg
Study: 2931040
Drug: Procaterol metered-dose
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol metered-dose inhaler
Study: 18929702
Drug: Thienopyridine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine therapy continued beyond 1 year
Study: 18929702
Drug: Thienopyridine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine therapy discontinued after 1 year
Study: 11431603
Drug: Nasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin administration (gelified form)
Study: 11431603
Drug: Subcutaneous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous regular insulin injections
Study: 8027276
Drug: Nafarelin acetate
Normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafarelin acetate (nasal spray)
Study: 8027276
Drug: Buserelin acetate
Normalized name: buserelin acetate
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin acetate (nasal spray)
Study: 2513939
Drug: Three days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days' treatment with co-trimoxazole 960 mg twice a day
Study: 2513939
Drug: Seven days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days' treatment with co-trimoxazole 960 mg twice a day
Study: 31705450
Drug: Boiled dill
Normalized name: Dill
DrugBank: Dill (DB10673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled dill seed (10 g boiled in 100 mL for 10 min, given orally at the beginning of active phase)
Study: 31705450
Drug: Oxytocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10 IU in 1000 mL of Ringer solution)
Study: 27320685
Drug: PDL-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL-only treatment
Study: 27320685
Drug: rapamycin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapamycin monotherapy
Study: 25399948
Drug: Shortened (46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened (46 weeks), intensified therapy
Study: 23221935
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day of encapsulated WGOE
Study: 18649754
Drug: Cernilton 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton 750 mg, twice a day for 4 years
Study: 18649754
Drug: Cernilton 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton 375 mg, twice a day for 4 years
Study: 18649754
Drug: Cernilton 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton 750 mg
Study: 18649754
Drug: Cernilton 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton 375 mg
Study: 17050212
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (baseline)
Study: 10978253
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (182 mg of RRR‐alpha‐tocopherol acetate per day)
Study: 10978253
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg of slow release ascorbate per day)
Study: 10978253
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin E and C
Study: 1346413
Drug: Clindamycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (300 mg twice daily)
Study: 6593316
Drug: 100 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 rad X 18 cranial radiation therapy
Study: 6593316
Drug: 180 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 rad X 10 cranial radiation therapy
Study: 30885073
Drug: Ertapenem (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (one dose)
Study: 30885073
Drug: Ampicillin, gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, gentamicin, and clindamycin (AGC-1, one-time intravenous dose)
Study: 20664838
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with beta‐tricalcium phosphate (b‐TCP)
Study: 20664838
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with collagen containing anorganic deproteinized bovine bone (xenograft)
Study: 20664838
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with either b‐TCP or xenograft
Study: 14499772
Drug: Lansoprazole, clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, clarithromycin, and amoxicillin (LCA)
Study: 10655965
Drug: EPA/DHA (1.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA (1.05 g EPA plus 0.55 g DHA)
Study: 10655965
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (6.8 g/d)
Study: 2065506
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid injection (1 or 2 knees)
Study: 6132218
Drug: Low-residue liquid
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-residue liquid supplement
Study: 12784123
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg THC
Study: 12784123
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg THC
Study: 24164904
Drug: Rabeprazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Study: 22389273
Drug: No supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplementation with oral nutrients (standard diet)
Study: 18398307
Drug: Purified Chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Chick Embryo Cell Vaccine (PCECV) administered as a three-dose regimen (1.0 mL or 0.5 mL)
Study: 18398307
Drug: Purified Verocell
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Verocell Rabies Vaccine (PVRV) administered as a three-dose regimen (0.5 mL)
Study: 10912985
Drug: Control (acid‐mantle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (acid‐mantle cream)
Study: 9072226
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration of T3
Study: 1984366
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine with 1:200,000 epinephrine through the single catheter
Study: 1984366
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% bupivacaine with or without 1:200,000 epinephrine through each of the two catheters
Study: 6407054
Drug: Clobazam 20
Normalized name: cloBAZam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 20 mg (an anxiolytic 1,5‐benzodiazepine derivative)
Study: 26095194
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml 0.25% bupivacaine (Group B)
Study: 26095194
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml saline (Group S)
Study: 23536104
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose drink
Study: 16701989
Drug: Once-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily budesonide/formoterol (80/4.5 microg, 2 inhalations in the evening)
Study: 16701989
Drug: Twice-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily budesonide/formoterol (80/4.5 microg, 1 inhalation)
Study: 16701989
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 microg, 1 inhalation in the evening)
Study: 16701989
Drug: Budesonide/formoterol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol therapy
Study: 15243815
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (specifics not provided)
Study: 15243815
Drug: C(6) antibody
Normalized name: FD & C Yellow #6
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(6) antibody testing
Study: 11345361
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogen daily for three months
Study: 3044484
Drug: Cephradine prophylaxis
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephradine prophylaxis (3 peri-operative doses)
Study: 23067311
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GSK1144814
Study: 19840020
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDChT) with autologous stem cell support (ASCS)
Study: 19840020
Drug: Sequential HD
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HD regimen with one or two conventional chemotherapy cycles followed by two or three HD cycles of CE
Study: 19840020
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDChT)
Study: 11871864
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy
Study: 16998274
Drug: Fasudil hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil hydrochloride (30 mg by intravenous injection over 30 minutes three times a day for 14 days)
Study: 16998274
Drug: Nimodipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (1 mg/hr by continuous intravenous infusion for 14 days)
Study: 9494056
Drug: Lifestyle program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle program including a low-fat diet and weekly moderate exercise (Experimental group, N = 27)
Study: 3668249
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-selective agent) with or without diuretics and/or vasodilators
Study: 24015934
Drug: NEURO (low-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEURO (low-frequency repetitive transcranial magnetic stimulation plus occupational therapy)
Study: 24015934
Drug: constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: constraint-induced movement therapy
Study: 12814142
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (AB) 1 mg/kg/day (weight < 75 kg = 50 mg/day; weight ≥ 75 kg = 100 mg/day)
Study: 22479740
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 100 mg once daily for 72 hrs
Study: 22479740
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 100 mg i.v. 6 hourly for 72 hrs
Study: 23283393
Drug: Thrice BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice BCG vaccinations (0.1 mL intradermal injection, 3 times every 4 weeks)
Study: 23283393
Drug: Single BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single BCG vaccination (0.1 mL intradermal injection)
Study: 17190103
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution with Na/K molar ratio of 1
Study: 17190103
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution with Na/K molar ratio of 2
Study: 17190103
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution with Na/K molar ratio of 3
Study: 17190103
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution with Na/K molar ratio of 4
Study: 8575136
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) at 3-5 mg/kg/day
Study: 8575136
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Methotrexate (MTX) at 2.5 mg every 12 hours for 3 consecutive doses each week up to 15 mg/week
Study: 2791446
Drug: 3200 mg
Normalized name: sodium chloride 3200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3200 mg ibuprofen
Study: 31273459
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (all three diagnoses)
Study: 26001510
Drug: High-rate therapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-rate therapy
Study: 26001510
Drug: Long-delay therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-delay therapy
Study: 24113668
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (b-INS)
Study: 21586650
Drug: CoQ10 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (100 mg)
Study: 16926172
Drug: new formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: new formulation (vitamins B1, B2, B6, B12, and folic acid)
Study: 16926172
Drug: old formulation
Normalized name: Poly Hist PD (old formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: old formulation (vitamins B1, B2, B6, and B12)
Study: 11390122
Drug: Aerodiol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerodiol 300 microg daily
Study: 11390122
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol (50 microg/day, 2 patches per week)
Study: 8313635
Drug: 1% griseofulvin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% griseofulvin spray applied twice daily for 14 days
Study: 8313635
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) applied twice daily for 14 days
Study: 8313635
Drug: 1% griseofulvin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% griseofulvin spray applied once daily for 4 weeks
Study: 8313635
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) applied once daily for 4 weeks
Study: 28810251
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg q.d. for 1 month followed by 5 mg q.d. for maintenance
Study: 28810251
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg b.i.d. for 1 month followed by 45 mg b.i.d. for maintenance
Study: 28810251
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg q.d. for 1 month followed by standard dose without reduction
Study: 25412795
Drug: ALV 600
Normalized name: ALV-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV 600 mg QD + PR
Study: 25412795
Drug: ALV 800
Normalized name: ALV-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV 800 mg QD + PR
Study: 25412795
Drug: ALV 400
Normalized name: ALV-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV 400 mg BID + PR
Study: 22324720
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% tacrolimus ointment
Study: 25262434
Drug: Rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5 mg/day)
Study: 16248952
Drug: Tumor vaccine
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor vaccine
Study: 16795983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (adjuvant treatment only)
Study: 16795983
Drug: DTH response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DTH response positive patients (from tumor vaccine group)
Study: 14515287
Drug: Postoperative portal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative portal vein infusion (PVI) of 5‐fluorouracil (5‐FU) (1 g 5‐FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24‐h period for 7 days)
Study: 14515287
Drug: Rectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal cancer
Study: 11113418
Drug: Mechanical force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical force of injection at 90 minutes
Study: 11113418
Drug: Overall intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall intervention (hand injection)
Study: 11113418
Drug: Hand injections
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand injections
Study: 6229319
Drug: gallamine (0.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallamine (0.29 mg X kg‐1)
Study: 6229319
Drug: d‐tubocurarine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine (0.04 mg X kg‐1)
Study: 6229319
Drug: metocurine (0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: metocurine (0.014 mg X kg‐1)
Study: 6229319
Drug: pancuronium (0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium (0.007 mg X kg‐1)
Study: 26915605
Drug: Nefiracetam 900
Normalized name: Nefiracetam
DrugBank: Nefiracetam (DB13082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefiracetam 900 mg/day for 12 weeks